Endopyelotomy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Endopyelotomy is a minimally invasive endoscopic procedure that treats ureteropelvic junction (UPJ) obstruction — a narrowing at the point where the renal pelvis drains into the ureter — by making a precisely placed incision through the full thickness of the obstructed segment under direct vision, then maintaining the widely open lumen with a temporary ureteral stent while the incised wall heals in a functionally open position. The UPJ is a common site of obstruction that, when significant, impairs drainage of urine from the kidney, leading to hydronephrosis (pelviocalyceal distension), flank pain particularly after fluid loading ('Dietl's crisis'), recurrent urinary tract infections, kidney stones, and, if severe and prolonged, progressive reduction of ipsilateral renal function. UPJ obstruction may be congenital — caused by a high insertion of the ureter, kinking, adhesions, or an intrinsic aperistaltic segment of ureteral wall — or acquired as a result of prior surgery, stone passage, or urothelial scarring. Endopyelotomy achieves its effect through incision of the narrowed segment, allowing the ureter to heal open to a larger calibre; it does not address crossing lower-pole renal vessels, which are present in 20–30% of UPJ obstructions and are a major predictor of failure. Alternatives include laparoscopic or robotic pyeloplasty, the gold-standard procedure with superior long-term success, and in children, open dismembered pyeloplasty remains widely practised.

Endopyelotomy is indicated for symptomatic UPJ obstruction — defined as obstruction associated with clinical symptoms (flank pain, recurrent infections, stone formation) and objective evidence of impaired drainage on diuretic renography (typically T½ more than 20 minutes) or significant and progressive hydronephrosis on serial ultrasound. Patient selection for endopyelotomy rather than pyeloplasty is guided by several factors: endopyelotomy is preferred for secondary UPJ obstruction following previous failed pyeloplasty, where the absence of crossing vessels has been confirmed by CT angiography or Doppler ultrasound, and where renal function on the affected side exceeds 25% of total function (below this threshold, pyeloplasty offers little functional benefit and pyeloplasty or nephrectomy is considered). The ideal candidate is an adult with a short, thin narrowing of the UPJ without crossing polar vessels, acceptable renal function, and no active urinary tract infection at time of surgery. Endopyelotomy carries a success rate of 70–85% in carefully selected patients without crossing vessels, compared with 85–90% for retrograde endopyelotomy and 93–95% for laparoscopic pyeloplasty, making pyeloplasty the preferred option for primary UPJ obstruction in most centres.

Two endoscopic approaches are used depending on anatomy, previous procedures, and surgeon preference. Retrograde ureteroscopic endopyelotomy: under general or spinal anaesthesia, a flexible ureteroscope is passed transurethrally through the bladder and advanced up the ureter to the UPJ under fluoroscopic guidance. The narrowed segment is identified under direct vision. Using a cold knife or a holmium:YAG laser set to a cutting mode, a single full-thickness incision is made through the posterolateral wall of the UPJ (away from crossing vessels), extending 1–2 cm above and below the narrowest point to ensure complete release of the obstruction. A guidewire is left in place and an internal ureteral stent — typically an endopyelotomy stent with a wider proximal portion (14 Fr) to maintain the newly created lumen — is inserted over the guidewire. Antegrade percutaneous endopyelotomy: in cases where retrograde access is technically difficult or has previously failed, a percutaneous nephrostomy provides access through the posterior renal calyx. An Acucise cutting balloon catheter or a cold knife electrode is passed through the nephrostomy and the UPJ incised under fluoroscopic guidance. A nephrostomy tube and ureteral stent are placed for drainage. The stent is left in place for 4–6 weeks before removal via a brief outpatient cystoscopy.

The principal benefit of endopyelotomy over open or laparoscopic pyeloplasty is its minimally invasive nature: no abdominal incisions are required for the retrograde approach, hospital stay is 1–2 days, and recovery time is 2–4 weeks compared with 4–6 weeks for laparoscopic pyeloplasty and 6–8 weeks for open surgery. For patients with secondary UPJ obstruction after a previous pyeloplasty, endopyelotomy avoids the technical difficulties of re-do open surgery in a scarred field and achieves success rates of 70–80% — comparable to or better than re-do pyeloplasty in experienced hands. The reversibility of endopyelotomy is another advantage: if the procedure fails to resolve the obstruction on follow-up renal scan, laparoscopic or robotic pyeloplasty can still be performed as a definitive second procedure without having compromised the anatomy. In the carefully selected patient — short UPJ narrowing, no crossing vessels, adequate renal function — endopyelotomy provides durable relief of obstruction with minimal invasiveness, avoiding major surgery and its associated risks.

The primary risk of endopyelotomy is failure to resolve the obstruction: success rates of 70–85% for carefully selected patients mean that 15–30% require further intervention. Crossing vessels — the most important predictor of failure — cause persistent obstruction because incision of the UPJ over a crossing vessel risks haemorrhage and, if the vessel is damaged, ischaemia of the lower renal pole. Pre-operative CT angiography is used to identify crossing vessels and exclude patients with this anatomy. Haemorrhage requiring blood transfusion or embolisation occurs in 1–5% and is more common with the percutaneous antegrade approach (given its proximity to renal vessels) than retrograde ureteroscopy. Urinary tract infection with the stent in situ affects 10–15% and is managed with antibiotics. Stent-related symptoms — urinary frequency, urgency, and flank discomfort — are universal while the stent is indwelling and resolve promptly after stent removal. Urinoma (urinary leak) at the incision site during healing is managed conservatively with the indwelling stent providing drainage. Late ureteral stricture from inadequate incision healing is rare. Perforation or avulsion of the ureter, though very rare with experienced endoscopists, may require emergency open or laparoscopic repair.

Hospital stay after retrograde endopyelotomy is typically 1–2 days. A urinary catheter is removed the morning after surgery and patients are discharged when comfortable and voiding satisfactorily. The internal ureteral stent remains in place for 4–6 weeks, during which urinary frequency, urgency, and mild haematuria are expected. Stent removal is performed as a 15-minute outpatient cystoscopy under local anaesthetic jelly or brief intravenous sedation. Adequate hydration (2–3 litres daily) reduces infection and stone risk while the stent is indwelling. Antibiotics are prescribed throughout the stenting period, or as prophylaxis at stent removal. Return to desk work is possible at 1–2 weeks for retrograde endopyelotomy. Physical activity is gradually increased from week 2. Heavy lifting is avoided for 4 weeks. Follow-up nuclear diuretic renography (MAG3 or DTPA scan) at 3–6 months is essential to objectively confirm drainage improvement and procedural success. If the T½ remains prolonged on the follow-up scan, management options including further observation, repeat endopyelotomy, or laparoscopic pyeloplasty are discussed with the patient.